ERAS-0015 Yields Early Partial Responses at 8 mg QD, Data Due H1 2026
In the AURORAS-1 Phase 1 trial, Erasca’s ERAS-0015 achieved two confirmed and one unconfirmed partial responses at an 8 mg QD dose with no dose-limiting toxicities and linear pharmacokinetics. The company targets initial monotherapy data for ERAS-0015 in the first half of 2026 and ERAS-4001 in the second half.
1. Insider Sale by General Counsel Reduces Direct Stake
On January 7, Erasca’s general counsel and corporate secretary, Garner Ebun, exercised options on 120,000 shares and immediately sold them in the open market for gross proceeds of $670,812, as reported in a recent SEC Form 4 filing. The transaction used a weighted average purchase price of $5.59 per share and left Ebun with 25,076 directly held shares valued at approximately $129,600 based on the same $5.59 price. This sale reduced direct common stock holdings by 82.7%, from 145,076 to 25,076 shares. No indirect transfers, gifts or withholdings were involved, and the sale was executed pursuant to a Rule 10b5-1 plan established in June 2024. Ebun still holds 360,000 outstanding options (vested and unvested), preserving significant upside exposure and alignment with long-term value creation.
2. Strong Market Appreciation Frames Insider Liquidity Event
Erasca’s share price has appreciated 189.8% over the past year, closing at $5.17 on January 7, 2026. The timing of Ebun’s option exercise and sale captured this rally, monetizing a period of significant stock performance. With a market capitalization of $1.77 billion and a trailing-twelve-month net loss of $127.7 million, the company remains in a growth phase underpinned by clinical-stage oncology programs. Investors may interpret the insider transaction as a non-dilutive liquidity event rather than a signal of diminished confidence, given its ties to compensation and long-standing option plan, but will monitor future sales capacity and continued insider alignment.
3. Clinical Progress of Lead RAS/MAPK Pathway Candidates
Erasca’s clinical pipeline centers on three targeted cancer therapies: ERAS-007 (ERK1/2 inhibitor), ERAS-601 (SHP2 inhibitor) and ERAS-801 (CNS-penetrant EGFR inhibitor), with early Phase 1 data emerging for ERAS-0015 and ERAS-4001. ERAS-0015, a pan-RAS molecular glue, has shown confirmed and unconfirmed partial responses at doses as low as 8 mg once daily, favorable safety (no dose-limiting toxicities) and linear pharmacokinetics in the AURORAS-1 trial. ERAS-4001, a pan-KRAS inhibitor in BOREALIS-1, continues dose escalation as planned. The company had $362 million in cash at year-end, expected to fund operations into H2 2028. Upcoming catalysts include first monotherapy data for ERAS-0015 in H1 2026, ERAS-4001 data in H2 2026, expansion cohorts and combination studies in 2027.